Multiple myeloma (MM) is the second most common hematological malignancy of plasma
cells, characterized by osteolytic bone lesions, anemia, hypercalcemia, renal failure, and the …

Cancer is a disease that undergoes selective pressure to evolve during its progression,
becoming increasingly heterogeneous. Tumoral heterogeneity can dictate therapeutic …

The DNA damage response (DDR) network and the mitogen-activated protein kinase
(MAPK) signaling pathway are crucial mechanisms for the survival of all living beings. An …

Optical genome map** (OGM) is a new genome-wide technology that can reveal both
structural genomic variations (SVs) and copy number variations (CNVs) in a single assay …

Simple Summary Autophagy is a dynamic and tightly regulated process that seems to have
dual effects in cancer. In some contexts, it can induce carcinogenesis and promote cancer …

Histone variants, which generally differ in few amino acid residues, can replace core
histones (H1, H2A, H2B, and H3) to confer specific structural and functional features to …

A deeper understanding of basic immunology principles and advances in bioengineering
have accelerated the mass production of genetically-reprogrammed T-cells as living drugs …

Multiple myeloma is a hematological cancer caused by the uncontrolled proliferation of
abnormal plasma cells in the bone marrow, leading to excessive immunoglobulin …

Telomere dysfunction is a notable event observed in many cancers contributing to their
genomic instability. A major factor controlling telomere stability is the human telomerase …

Multiple myeloma (MM) is a hematological malignancy in which monoclonal plasma cells
multiply in the bone marrow and monoclonal immunoglobulins are overproduced in older …